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Editorial
New Normal for Medical Practice Post COVID-19?
David B. Nash, MD, MBA
As I write, the United States has been held captive for thebetter part of a year. Across the nation, COVID-19 has
spawned fear, anxiety, disruption, and tragedy. It also has
forced professionals in every sector to confront new realities
and reassess the ways in which they attend to ‘‘business as
usual.’’
The traditional ‘‘art’’ of medicine relies heavily on face-to-
face contact - close visual inspection, touch/palpation, picking
up on a wide range of sensory and behavioral diagnostic clues.
However, the critical need for social distancing to reduce the
spread of COVID-19 has accelerated an inevitable shift from
in-person to virtual communication. One positive consequence
of this is that it forces us to take a hard look at the way we
practice medicine.
Already an accepted mode of health care delivery in the
United States, there is convincing evidence that telehealth
is efficient, effective, and beneficial for specific uses and
patient populations.1 This supplement focuses on one such
population.
A substantial population of women with symptoms of
vaginitis make up to 10 million outpatient visits per year2 with
associated costs approaching $1.3 billion.3 The current stan-
dard of care calls for a visual examination of external and
internal structures as well as vaginal secretions, a ‘‘whiff test’’
to detect distinctive odors associated with specific infections,
and on-site pH and wet mount diagnostic tests. A bimanual
exam is also recommended.
There are several common causes of vaginitis, and dif-
ferential diagnosis is challenging even under ‘‘normal’’
conditions. The literature suggests that a large percentage of
patients do not receive an optimal diagnostic evaluation.
The expected shift from in-person to virtual outpatient visits
likely will further complicate the diagnostic dilemma.
To me, the implications are clear: it is time to reconsider
how best to approach care for this patient population under
‘‘the new normal’’ conditions. There is an obvious synergy
between telehealth visits and state-of-the-art molecular tech-
nology that can be leveraged to improve the efficiency and
accuracy of care we provide to women with vaginitis.
I hope that, in addition to drawing needed attention to an
important population health issue, this supplement leads cli-
nicians, professional organizations, payers, and policy makers
to revisit ‘‘business as usual’’ with an eye toward optimizing
health care now and into the future.
References
1. Agency for Healthcare Research and Quality. The evidence
base for telehealth: reassurance in the face of rapid expan-
sion during the COVID-19 pandemic. https://effectivehealth
care.ahrq.gov/sites/default/files/pdf/telehealth-commentary-
white-paper.pdf
2. Granato P. Vaginitis: clinical and laboratory aspects for di-
agnosis. Clinl Microbiol Newsl 2010;32:111–116.
3. Peebles K, Volloza J, Balkus J, McClelland RS, Barnabas R.
High global burden and costs of bacterial vaginitis: a sys-
temic review and meta-analysis. Sex Transm Dis 2019;45:
304–311.
Address correspondence to:
David B. Nash, MD, MBA
Jefferson College of Population Health




Jefferson College of Population Health, Philadelphia, Pennsylvania, USA.
David B. Nash, 2020; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative
Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
POPULATION HEALTH MANAGEMENT
Volume 23, Supplement 1, 2020
ª Mary Ann Liebert, Inc.
DOI: 10.1089/pop.2020.29003.nas
S-1
